Functional ligands to opioids and opioid derivatives
Inventors
Kaur, Jasmine • Drabek, Rafal • Jackson, George W. • Batchelor, Robert • Chiu, Alexander
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Base Pair BiotechnologiesBase Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Publication Number
US-11725240-B2
Publication Date
2023-08-15
Expiration Date
Abstract
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as opioids and opioid derivatives.
Core Innovation
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as opioids and opioid derivatives, such as acetyl fentanyl, carfentanil, and naloxone.
The background describes that aptamers are commonly identified by an in vitro method of selection sometimes referred to as Systematic Evolution of Ligands by EXponential enrichment or “SELEX”. SELEX typically begins with a very large pool of randomized polynucleotides which is generally narrowed to one aptamer ligand per molecular target.
Claims Coverage
This patent includes two independent inventive features extracted from the independent claims.
Non-naturally occurring nucleic acid under 40 nucleotides with greater than 90% identity to SEQ ID Nos. 1-10
An artificial ligand binding to acetyl fentanyl comprising a non-naturally occurring nucleic acid sequence of under 40 nucleotides in length having greater than 90% sequence identity to a sequence selected from the group consisting of SEQ ID Nos. 1-10.
Non-naturally occurring nucleic acid with 100% identity to SEQ ID Nos. 1-10
An artificial ligand binding to acetyl fentanyl comprising a non-naturally occurring nucleic acid sequence having 100% sequence identity to a sequence selected from the group consisting of SEQ ID Nos. 1-10.
The independent claims disclose two core inventions directed to artificial, non-naturally occurring nucleic acid ligands that bind acetyl fentanyl, one defined by sequences under 40 nucleotides with greater than 90% identity to SEQ ID Nos. 1-10 and the other defined by sequences with 100% identity to SEQ ID Nos. 1-10.
Stated Advantages
High-capacity, multiplexed identification procedures may save time, expense, and physical space for the process over single target identification processes.
The method may be utilized to identify and/or eliminate biomolecules that bind or have a tendency to bind to multiple targets.
Performing only the final binding and marking/tagging procedure on an array may be desirable because complex target arrays may generally be more expensive and/or difficult to make or utilize than solutions of target molecules.
Documented Applications
Detection, quantification, and/or other diagnostic applications for detection of opioids and opioid derivatives in body fluids or tissues.
Purification, separation, or other forms of analysis or processing of opioids and opioid derivatives.
Use in detection formats including backscattering interferometry (BSI), microscale thermophoresis (MST), biolayer interferometry (BLI), electrochemical sensors, gold nanoparticle assays, enzyme linked aptamer sorbent assays (ELASA), pull down assays (immunoprecipitation), microplate/well assays, cell sorting, and lateral flow assays.
Creation of molecular beacons (aptabeacons) that fluoresce or otherwise produce a detectable signal upon aptamer binding to a target molecule.
Interested in licensing this patent?